BioNexus Gene Lab Corp Common stock (BGLC)vsLinde plc Ordinary Shares (LIN)
BGLC
BioNexus Gene Lab Corp Common stock
$2.20
-4.14%
BASIC MATERIALS · Cap: $5.56M
LIN
Linde plc Ordinary Shares
$507.90
-0.40%
BASIC MATERIALS · Cap: $229.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Linde plc Ordinary Shares generates 652450% more annual revenue ($34.65B vs $5.31M). LIN leads profitability with a 20.4% profit margin vs -54.7%. LIN earns a higher WallStSmart Score of 62/100 (C+).
BGLC
Avoid26
out of 100
Grade: F
LIN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BGLC.
Margin of Safety
-70.2%
Fair Value
$298.47
Current Price
$507.90
$209.43 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 28.5%
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -35.9% — below average capital efficiency
Revenue declined 98.9%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BGLC
The strongest argument for BGLC centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : LIN
The strongest argument for LIN centers on Market Cap, Profit Margin, Operating Margin. Profitability is solid with margins at 20.4% and operating margin at 28.5%.
Bear Case : BGLC
The primary concerns for BGLC are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : LIN
The primary concerns for LIN are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BGLC profiles as a turnaround stock while LIN is a mature play — different risk/reward profiles.
BGLC carries more volatility with a beta of 2.19 — expect wider price swings.
LIN is growing revenue faster at 8.2% — sustainability is the question.
LIN generates stronger free cash flow (898M), providing more financial flexibility.
Bottom Line
LIN scores higher overall (62/100 vs 26/100), backed by strong 20.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioNexus Gene Lab Corp Common stock
BASIC MATERIALS · SPECIALTY CHEMICALS · USA
BioNexus Gene Lab Corp. The company is headquartered in Kuala Lumpur, Malaysia.
Linde plc Ordinary Shares
BASIC MATERIALS · SPECIALTY CHEMICALS · USA
Linde plc is a multinational chemical company. It is the largest industrial gas company by market share and revenue. It serves customers in the healthcare, petroleum refining, manufacturing, food, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, electronics and water treatment industries. The company's primary business is the manufacturing and distribution of atmospheric gases, including oxygen, nitrogen, argon, rare gases, and process gases, including carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene.
Visit Website →Compare with Other SPECIALTY CHEMICALS Stocks
Want to dig deeper into these stocks?